BAPTA-AM (Synonyms: BAPTA Acetoxymethyl ester) |
| Catalog No.GC13517 |
BAPTA-AM은 세포 내 칼슘 과부하를 줄여 세포 손상을 방지하는 막 투과성 Ca2+킬레이트 시약이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 126150-97-8
Sample solution is provided at 25 µL, 10mM.
BAPTA-AM은 세포 내 칼슘 과부하를 줄여 세포 손상을 방지하는 막 투과성 Ca2+킬레이트 시약이다.
MTT방법을 이용하여 BAPTA-AM의 IC50 수치를 연구하였다.유방암 4T1세포주에서의 BAPTA-AM의 IC50 수치는 13.6 µm이다.붕소테조미 (1nM， 10nM)와 BAPTA-AM (0.5µM, 5µM)의 용량별로 세포를 처리하여BAPTA-AM과BAPTA-AM의 결합 효과를 관찰하였다.10 nm 붕소 테조미와 5 µm BAPTA-AM을 병행하는 것이 단독으로 사용하는 것 (10 nM 붕소 테조미 또는 5 µM BAPTA-AM단독 사용)보다 더 효과적이다.
칼슘 킬레이터 이용한 연골세포 손상에 대한 시콜레이트 시약인 BAPTA-AM의 치료효과를 측정하였다. BAPTA-AM은 연골세포의 철함량을 현저히 감소시키고 철의 과부하로 인한 세포자살과 MMPs의 발현을 억제하여 철의 과부하로 인한 질병의 치료에 새로운 방향을 제공하였다.
IP3R과 Ca2+항상성을 회복시키는 BAPTA-AM 전처치법은HTV 유도 폐 손상과 염증반응을 감소시킨다. BAPTA-AM의 용량 의존적 효과를 평가하는 결과 2.5mg/kg은 HTV에 의한ER Ca2+의 과도한 방출을막기에 충분한 것으로 나타났다.폐조직의 병리학적 변화, W/D비율, BALF단백질 함량, 세포침윤수 및 염증인자인IL-1 β, IL-6과 TNF-α 수치를 관찰하였다.
References:
[1]. Fu Z, Fan Q, et al. Elimination of Intracellular Calcium Overload by BAPTA-AM-Loaded Liposomes: A Promising Therapeutic Agent for Acute Liver Failure. ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39574-39585.
[2]. Yerlikaya A, Erdoğan E, et al. A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib. Oncol Lett. 2016 Jul;12(1):323-330.
[3]. Jing X, Wang Q, et al. Calcium chelator BAPTA AM protects against iron overload induced chondrocyte mitochondrial dysfunction and cartilage degeneration. Int J Mol Med. 2021 Oct;48(4):196.
[4]. Ye L, Zeng Q, et al.Inhibition of IP3R/Ca2+ Dysregulation Protects Mice From Ventilator-Induced Lung Injury via Endoplasmic Reticulum and Mitochondrial Pathways. Front Immunol. 2021 Sep 15;12:729094.
| 세포 실험 [1]: | |
세포 라인 | 활짝세포 |
제조 방법 | 활짝세포는 100 µm FAC로 처리되었으며, BAPTA-AM이 포함되거나 포함되지 않았습니다. 세포 내 철분은 0.5 mm 칼세인-AM으로 15분 동안 염색한 다음 공간 현미경으로 관찰하여 활짝세포 내 철분 흡수 및 방출을 평가했습니다. |
반응 조건 | 10 µM BAPTA-AM， 3일 동안 |
응용 분야 | 철분 첨합제인 BAPTA-AM은 활짝세포에서 철분 유입을 억제합니다. FAC 처리 그룹의 유플로레센스 강도가 현저하게 감소하여 활짝세포 내 철분 함량이 증가함을 나타냅니다. 반면, BAPTA-AM 공동 처리 그룹의 유플로레센스 강도가 현저하게 증가하여 BAPTA-AM 공동 처리가 활짝세포 내 철분 농도를 감소시켰음을 나타냅니다. |
| 동물 실험 [2]: | |
동물 모형 | C57BL/6 쥐 |
제조 방법 | 쥐는 Ca2+ 첨합제인 BAPTA-AM으로 사전 처리되었습니다. 폐 조직과 기관지 폐알비 공동세척액(BALF)을 수집하여 Ca2+ 농도, 염증 반응, 그리고 내질망 스트레스, NLRP3 인플라마소메 활성화 및 염증과 관련된 mRNA/단백질 표현을 측정했습니다. |
제형 | 1.25, 2.5, 5 mg/kg BAPTA-AM, 복강 주사(i.p.) |
응용 분야 | BAPTA-AM의 용량에 따라 영향을 평가한 결과, 2.5mg/kg은 HTV가 유도한 내질망 Ca2+ 과다 방출을 방지하기에 충분했습니다. HTV가 유도한 폐 뇌수종과 손상은 BAPTA-AM 치료로 개선되었습니다. 일관되게 카바콜의 존재 하에서 BALF의 IL-1β, IL-6 및 TNF-α 농도가 현저하게 증가했으며, BAPTA-AM은 BALF 사이토카인 수준의 증가를 차단했습니다. |
참고문헌: [1]. Jing X, Wang Q, et al.Calcium chelator BAPTA AM protects against iron overload induced chondrocyte mitochondrial dysfunction and cartilage degeneration. Int J Mol Med. 2021 Oct;48(4):196. [2]. Ye L, Zeng Q, et al.Inhibition of IP3R/Ca2+ Dysregulation Protects Mice From Ventilator-Induced Lung Injury via Endoplasmic Reticulum and Mitochondrial Pathways. Front Immunol. 2021 Sep 15;12:729094. | |
| Cas No. | 126150-97-8 | SDF | |
| Synonyms | BAPTA Acetoxymethyl ester | ||
| Canonical SMILES | O=C(CN(CC(OCOC(C)=O)=O)C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(OCOC(C)=O)=O)CC(OCOC(C)=O)=O)OCOC(C)=O | ||
| Formula | C34H40N2O18 | M.Wt | 764.68 |
| Solubility | ≥ 16.3mg/mL in DMSO with gentle warming | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3077 mL | 6.5387 mL | 13.0774 mL |
| 5 mM | 0.2615 mL | 1.3077 mL | 2.6155 mL |
| 10 mM | 0.1308 mL | 0.6539 mL | 1.3077 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Excessive intracellular Ca2+ concentration activates calpain to degrade the microtubule of N2a cells.(D) SK-N-SH cells were transfected with Vector or CVS-M-FLAG for 36 h or transfected with CVS-M-FLAG for 12 h and treated with BAPTA-AM (25 µM) for 24 h; lysates were analyzed by WB.
N2a cells were transfected with Vector or CVS-M-FLAG for 12 h; then, cells were treated with DMSO, EGTA-AM, BAPTA-AM (Glpbio) (25 µM), Calpain inhibitor III, or Z-VAD-FMK for 24 h; lysates were analyzed by WB.
Mbio (2024). PMID: 38349129 IF: 6.3996 -
Related Biological Data
Different dihydropyridine-derived calcium channel blockers inhibit HTNV infection. (C) Huh7 cells were infected with HTNV upon treatment with BAPTA-AM, 24 hpi.
The calcium chelator BAPTA-AM was purchased from GlpBio (Montclair, CA, United States).
Front Pharmacol 13 (2022): 940178. PMID: 36105208 IF: 5.6 -
Related Biological Data
The PLC/IP3R/STIM-dependent Ca2+ channel inhibitors attenuate histone-induced apoptosis and defective bacterial phagocytosis in macrophages. A–D The percentage of apoptotic cells was quantified by Annexin V-FITC/PI staining.
To explore the effect of BAPTA-AM on histone-induced macrophage damage in CLP mice, mice were pretreated intraperitoneally with BAPTA-AM (GlpBio) (7.5 mg/kg) for 30 min and then subjected to CLP, followed by intravenous injection of histones (20 mg/kg).
Int Immunopharmacol 132 (2024): 111870. PMID: 38547771 IF: 5.5999 -
Related Biological Data
Isoflurance preconditioning was involved in intracellular Ca2+ of liver macrophages. C. The activation of NF-KB in KCs was examined by laser scanning confocal microscope (600×).
BAPTA-AM (GLPBIO, USA), a selective calcium chelator, was used to inhibit intracellular Ca2+.
Int Immunopharmacol 99 (2021): 107977. PMID: 34332342 IF: 4.93 -
Related Biological Data
The effects of BAPTA-AM on the IP3R-MCU calcium regulation axis in GC-1 spg cells.GC-1 spg cells were pretreated with BAPTA-AM before CdCl2 exposure. The mRNA expression levels in GC-1 spg cells were detected by RT-PCR.
However, BAPTA-AM (GlpBio) (10μM or 15μM) significantly increased the viability of the GC-1spg cells inhibited by CdCl2.
Toxicology (2023): 153448. PMID: 36731763 IF: 4.571 -
Related Biological Data
Activation of Piezo1 promoted chondrocytes senescence through Ca2+ accumulation. A and B. Representative fluorescence imaging of intracellular Ca2+, ROS and mean fluorescence intensity of chondrocytes after Yoda1 or BAPTA-AM treatment.
When primary chondrocytes proliferated to 80% density, they were intervened with 5 mM Yoda1 with or without 10 mM BAPTA-AM (GLPBio, GC13517) for 24 h, as in the previous study.
Biochem Bioph Res Co (2022). PMID: 35367826 IF: 3.5753
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *